NCT06470178View on ClinicalTrials.gov

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Not yet recruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Colorectal Cancer
Interventions
COMBINATION_PRODUCT

corhot1: chemotherapy combined with fruquintinib

"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."

COMBINATION_PRODUCT

corhot2: chemotherapy combined with fruquintinib

"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."

Trial Locations (1)

430000

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

Wuhan University

OTHER